You are viewing: GCC Countries AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The GCC Countries AI in Oncology Market was valued at $33.8 Million in 2024 and projected to reach to $144.3 Million by 2029, representing a compound annual growth rate of 27.4%. The GCC Countries AI in Oncology Market is poised for exceptional growth through 2029, driven by substantial healthcare investments, rising cancer incidence rates, and government initiatives promoting digital health transformation.

GCC Countries AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

GCC Countries AI in Oncology Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 27.4%, reflecting strong regional investment in healthcare technology and oncology innovation.
  • GCC Countries are increasingly adopting AI-driven diagnostic and treatment solutions to enhance cancer care delivery and improve patient outcomes across the region. GCC Countries' healthcare infrastructure and government support for digital transformation are key catalysts driving market growth.
  • The region's focus on precision medicine, coupled with rising cancer incidence and demand for advanced treatment options, positions GCC Countries as a high-growth market within the Middle East and Africa segment.
  • Between 2024 and 2029, GCC Countries will likely see significant deployment of AI algorithms for tumor detection, treatment planning, and clinical decision support systems..

Key Market Statistics

  • CAGR (2024-2029) 27.4% CAGR
  • Market Size, 2024 ~USD 33.8 Million
  • Forecast, 2029 ~USD 144.3 Million
  • Country GCC Countries

GCC Countries AI in Oncology Market Overview

Rapid Market Expansion :

The AI in Oncology Market in GCC Countries is growing at 27.4% CAGR, significantly outpacing global healthcare technology adoption rates and demonstrating strong regional commitment to advanced cancer care solutions.

Substantial Investment Growth :

Market valuation is projected to grow from USD 33.8 million in 2024 to USD 144.3 million by 2029, representing a 327% increase over five years and reflecting GCC governments' prioritization of oncology innovation.

Healthcare Technology Leadership :

GCC Countries are positioning themselves as regional hubs for AI-driven diagnostic and treatment solutions, leveraging advanced infrastructure and healthcare spending to attract international oncology technology providers.

Strategic Regional Adoption :

Increasing implementation of AI-powered precision medicine, early detection systems, and personalized treatment planning across major GCC healthcare institutions and private oncology centers.

GCC Countries AI in Oncology Market Dynamics

  • Regional healthcare providers are increasingly integrating AI solutions for diagnostic imaging, treatment planning, and patient outcome prediction, supported by advanced medical infrastructure and high healthcare expenditure per capita. Key growth catalysts include partnerships between GCC healthcare systems and global AI technology leaders, regulatory frameworks supporting medical AI adoption, and growing awareness among oncologists regarding AI's clinical benefits.
  • The region's focus on becoming a medical tourism destination further accelerates demand for cutting-edge oncology technologies, positioning GCC Countries as a critical market for AI oncology solution providers..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • GCC Countries' AI in Oncology Market is valued at USD 33.8 million in 2024 and expected to grow to USD 144.3 million by 2029, representing a 27.4% CAGR.
      • GCC Countries benefit from advanced healthcare infrastructure and government-backed digital health initiatives that accelerate AI adoption in oncology.
      • Rising cancer prevalence and demand for precision medicine in GCC Countries are driving investment in AI-powered diagnostic and treatment solutions.
      • GCC Countries are positioned as a high-growth regional market, attracting both local and international AI healthcare vendors through 2029.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      GCC Countries AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      Target Audience

      • Healthcare Technology Providers : AI and oncology software companies seeking to expand into high-growth GCC markets with detailed regional demand forecasts, adoption barriers, and customer segmentation data.
      • Investment Firms & Venture Capitalists : Private equity and venture capital investors evaluating oncology AI opportunities in GCC Countries require market sizing, growth trajectories, and competitive positioning analysis.
      • Hospital Networks & Healthcare Systems : GCC-based healthcare providers and oncology centers need market intelligence to benchmark AI adoption rates, evaluate technology partnerships, and plan digital transformation initiatives.
      • Medical Device & Pharma Companies : Pharmaceutical and medical device manufacturers expanding into GCC oncology markets require insights on AI integration opportunities and technology partnership potential.
      • Government & Health Policy Makers : GCC health ministries and regulatory bodies need market data to inform healthcare technology policies, procurement strategies, and digital health infrastructure investments.

      Reasons to Buy this Report

      • Market Entry Strategy : Comprehensive analysis of GCC-specific market dynamics, regulatory environment, and healthcare infrastructure to develop targeted market entry and localization strategies for oncology AI solutions.
      • Investment Decision Support : Detailed financial projections and growth forecasts specific to GCC Countries enable informed investment decisions, partnership evaluations, and resource allocation for oncology technology ventures.
      • Competitive Landscape Intelligence : In-depth understanding of regional competitors, key healthcare providers, technology adoption patterns, and market consolidation trends unique to GCC oncology sector.
      • Stakeholder Engagement : Identify and understand GCC-based hospital networks, government health authorities, private oncology centers, and technology integrators to facilitate strategic partnerships and collaborations.
      • Risk Mitigation : Assess regional regulatory requirements, reimbursement models, healthcare spending patterns, and cultural factors specific to GCC Countries to minimize market entry risks.

      Frequently asked questions

      What is the current market size of AI in Oncology in GCC Countries?

      The AI in Oncology Market in GCC Countries was valued at USD 33.8 million in 2024.

      What is the projected market size for AI in Oncology in GCC Countries by 2029?

      GCC Countries' AI in Oncology Market is forecast to reach USD 144.3 million by 2029.

      What is the CAGR for AI in Oncology in GCC Countries?

      GCC Countries' AI in Oncology Market is expected to grow at a compound annual growth rate of 27.4% from 2024 to 2029.

      What factors are driving AI adoption in oncology across GCC Countries?

      GCC Countries are driven by advanced healthcare infrastructure, government digital health initiatives, rising cancer incidence, and demand for precision medicine solutions.

      How does the GCC Countries market compare to the global AI in Oncology market?

      GCC Countries' CAGR of 27.4% is slightly lower than the global CAGR of 29.4%, but GCC Countries represents a high-growth regional opportunity within the Middle East and Africa segment.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status